R&D The hidden cost of rework in pharma facility builds If a facility is late or non-compliant, the entire supply chain can be compromised, from R&D labs to hospital shelves.
R&D How pharmaceutical companies can speed up construction proje... The pharmaceutical construction industry has seen explosive growth, a trend with substantial implications for healthcare industry, and global health outcomes.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
